Lilly’s New Anti-Amyloid Play Hinges On Tau Bet

Redesigned Phase III Trial May Confirm Phase II Donanemab Results

TRAILBLAZER-ALZ met the primary, but not most secondary endpoints. Lilly said efficacy of its amyloid-clearing agent depends on tau levels at baseline and reductions in some parts of the brain.

Poker chips on red background
Lilly's bet on donanemab depends on tau levels and tau burden reductions • Source: Shutterstock

Eli Lilly and Company is no stranger to the risky business of Alzheimer’s disease drug development, which may be why the big pharma is willing to place a high-risk bet on its newest amyloid-clearing therapy donanemab based on mixed results in the Phase II TRAILBLAZER-ALZ clinical trial. The company is converting its ongoing Phase IIb TRAILBLAZER-ALZ2 trial into a Phase III study, upping the number of patients and changing the endpoint to make its wager on donanemab a safer bet.

Lilly presented detailed results from TRAILBLAZER-ALZ during the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) and the data simultaneously...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from R&D

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.